DelveInsight’s “Molluscum Contagiosum Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Molluscum Contagiosum Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The market report covers emerging drugs, treatment practices, market share of individual Molluscum Contagiosum therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Molluscum Contagiosum treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Molluscum Contagiosum: An Overview
Molluscum Contagiosum, also called water warts, is a common superficial skin infection caused by the poxvirus. It predominantly affects school-aged children and immunocompromised individuals. The virus is transmitted mainly by direct contact with infected skin. It is common in children and generally presents with asymptomatic lesions; however, it can present with pruritus, erythema, and on some occasions, bacterial superinfections with inflammation and pain. Clinically, Molluscum Contagiosum presents as firm rounded papules, pink or skin-colored, with a shiny and umbilicated surface. It can be itchy, but most of the time, they are asymptomatic.
In normal hosts, Molluscum Contagiosum is benign natured limited to the skin, but lesions can take as long as 6–12 months to resolve. Immunocompromised patients can develop very large (than 15 mm) and numerous lesions and bacterial superinfections. Molluscum Contagiosum occurs worldwide and is more frequent in children, typically affecting 2–5 years old, being rare under the age of 1 year.
Molluscum Contagiosum Market Key Facts
-
The total number of prevalent cases of Molluscum Contagiosum in the 7MM countries was around 12.5 million in 2021.
-
In 2021, the US had the highest prevalent Molluscum Contagiosum cases, with around 6,250,000+ cases. While the lowest cases were recorded in Spain with ~680,000 cases.
-
Japan had about 1,330,000 prevalent cases of Molluscum Contagiosum in 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Molluscum Contagiosum therapies in the market. It also provides a detailed assessment of the Molluscum Contagiosum market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the market trend for each marketed Molluscum Contagiosum drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Molluscum Contagiosum Epidemiology
The epidemiology section covers detailed insights into the historical, and current Molluscum Contagiosum patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.
The Report Covers the Molluscum Contagiosum Epidemiology Segmented as –
-
Total Prevalent Population of Molluscum Contagiosum in the 7MM [2019–2032]
-
Gender-specific Cases of Molluscum Contagiosum in the 7MM [2019–2032]
Molluscum Contagiosum Drugs Uptake and Pipeline Development Activities
The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Molluscum Contagiosum market or expected to be launched during the study period. The analysis covers the market share by Molluscum Contagiosum drugs, patient uptake by therapies, and sales of each drug.
The report’s drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.
The report also covers the Molluscum Contagiosum Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover How the Molluscum Contagiosum Market Will Grow by 2032 @
https://www.delveinsight.com/sample-request/molluscum-contagiosum-mc-market
Molluscum Contagiosum Therapeutics Assessment
The major therapeutic modalities employed for Molluscum Contagiosum include physical destruction, immunomodulation, and antiviral agents, or combinations of these therapies. The physical destruction of lesions may be done by cryotherapy, curettage, laser, salicylic acid, and other methods; however, these procedures can be painful and engender scarring. Alternatively, immune-modulating therapies, such as topical imiquimod or cimetidine, have been used to speed the healing of Molluscum Contagiosum lesions; however, there is limited information to show these are effective, and imiquimod has known side effects.
Several major pharma and biotech companies are developing therapies for Molluscum Contagiosum. Currently, Novan Inc is leading the therapeutics market with its Molluscum Contagiosum drug candidates in the most advanced stage of clinical development.
Leading Companies in the Molluscum Contagiosum Therapeutics Market Include
-
Novan
-
Veloce Biopharma
-
Verrica Pharmaceuticals
-
Santalis Healthcare
-
Ligand Pharmaceuticals
And Many Others
Emerging and Marketed Molluscum Contagiosum Therapies Covered in the Report Include
-
SB 206 (Berdazimer Sodium): Novan Inc
-
VBP-245 (Povidone Iodine Topical): Veloce Biopharma
And Many More
Learn More About the Emerging Therapies and key Companies in the Molluscum Contagiosum Therapeutics Market @
https://www.delveinsight.com/sample-request/molluscum-contagiosum-mc-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Molluscum Contagiosum Competitive Intelligence Analysis
4. Molluscum Contagiosum Market Overview at a Glance
5. Molluscum Contagiosum Background and Overview
6. Molluscum Contagiosum Patient Journey
7. Molluscum Contagiosum Epidemiology and Patient Population
8. Molluscum Contagiosum Treatment Algorithm, Current Treatment, and Medical Practices
9. Molluscum Contagiosum Unmet Needs
10. Key Endpoints of Molluscum Contagiosum Treatment
11. Molluscum Contagiosum Marketed Products
12. Molluscum Contagiosum Emerging Therapies
13. Molluscum Contagiosum Seven Major Market Analysis
14. Attribute Analysis
15. Molluscum Contagiosum Market Outlook (7 major markets)
16. Molluscum Contagiosum Access and Reimbursement Overview
17. KOL Views on the Molluscum Contagiosum Market.
18. Molluscum Contagiosum Market Drivers
19. Molluscum Contagiosum Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Download the Sample PDF to Get Detailed Insights About the Report’s Offerings @
https://www.delveinsight.com/sample-request/molluscum-contagiosum-mc-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Listeriosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Listeriosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Listeriosis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology